Abstract: Provided herein are, inter alia, antibodies (e.g. humanized antibodies, monoclonal antibodies, antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 1 (ROR1) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR1-related diseases.

Abstract: Provided herein is a chimeric antigen receptor (CAR) and CAR-expressing immune cells that target human RORI expressed aberrantly on a tumor cancers. Described herein are chimeric antigen receptors that target human ROR-1, cell compositions expressing the chimeric antigen receptors, and methods and uses of the chimeric antigen receptors and/or the cell compositions. The chimeric antigen receptors described herein can be expressed by the T lymphocytes isolated from an individual afflicted with cancer and re-administered to the individual.

Abstract: The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF?, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF?, wherein the encoded domain or subdomain replaces a cleavage site of native TNF?, and a second nucleotide sequence encoding a domain or subdomain of native TNF? that binds to a TNF? receptor. The encoded chimeric TNF? is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF? receptor on the surface of a cell. The chimeric TNF? is therefore useful in methods for inducing apoptosis of a cell expressing a TNF? receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF? that is expressed on the surface of the cell.

Abstract: The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Abstract: The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Abstract: The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF?, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF?, wherein the encoded domain or subdomain replaces a cleavage site of native TNF?, and a second nucleotide sequence encoding a domain or subdomain of native TNF? that binds to a TNF? receptor. The encoded chimeric TNF? is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF? receptor on the surface of a cell. The chimeric TNF? is therefore useful in methods for inducing apoptosis of a cell expressing a TNF? receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF? that is expressed on the surface of the cell.

Abstract: The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Abstract: The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF?, comprising a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF?, wherein the encoded domain or subdomain replaces a cleavage site of native TNF?, and a second nucleotide sequence encoding a domain or subdomain of native TNF? that binds to a TNF? receptor. The encoded chimeric TNF? is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF? receptor on the surface of a cell. The chimeric TNF? is therefore useful in methods for inducing apoptosis of a cell expressing a TNF? receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF? that is expressed on the surface of the cell.

Abstract: The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Abstract: The present invention is directed to an isolated polynucleotide sequence encoding a chimeric TNF? and chimeric TNF? polypeptides. The former have a first nucleotide sequence encoding a domain or subdomain of a tumor necrosis factor ligand other than TNF?, wherein the encoded domain or subdomain lacks a cleavage site, and a second nucleotide sequence encoding a domain or subdomain of native TNF? that binds to a TNF? receptor. The encoded chimeric TNF? is significantly less susceptible to cleavage from the cellular surface and, as a result can increase the concentration of a ligand capable of binding to a TNF? receptor on the surface of a cell. The chimeric TNF? is therefore useful in methods for inducing apoptosis of a cell expressing a TNF? receptor, inducing activation of an immune system cell and treating neoplastic cells, by introducing into the cell of interest an isolated polynucleotide sequence encoding a chimeric TNF? that is expressed on the surface of the cell.

Abstract: The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences.

Abstract: A method of treating cancer by administering ISF35 or analogous constructs. The treatment can allow an increased sensitivity to treatment with a chemotherapeutic agent.

Abstract: The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The first nucleotide sequence preferably further encodes an extracellular subdomain of non-human CD154 that is critical for expression of said CD154 by cells, such as human CD40+ cells, and another extracellular domain that detects expression of the chimeric CD154 by binding to anti-murine antibodies. The second nucleotide sequence preferably further encodes an extracellular subdomain of human CD154 to which functionally inhibitory anti-CD154 antibodies bind.

Abstract: Methods for preserving an infectious recombinant virus for subsequent reconstitution are provided. Within one aspect, the method comprises the steps of (a) combining an infectious recombinant virus with an aqueous solution comprising a saccharide, a high molecular weight structural additive, a buffering component and water to form an aqueous suspension, thereby stabilizing the infectious virus; (b) cooling the aqueous suspension containing the virus to a temperature below the glass transition state temperature or below the eutectic point temperature of the formulation; and (c) removing water from the cooled aqueous suspension by sublimation to form a lyophilized virus having less than 10% water by weight of the lyophilized virus, the virus being capable of infecting mammalian cells upon reconstitution.

Abstract: Methods and compositions useful for the separation of viruses, including retroviruses and vital vectors, from preparations are disclosed. Sulfated oligosaccharides with at least about 6 .mu.moles sulfate per gram of oligosaccharide are provided. In one aspect, a sulfated oligosaccharide of the present invention may be used in the purification of a virus, such as a lipid envelope virus. The present invention also discloses methods for the removal of a contaminating virus from a preparation, such as biologic therapeutics.